Skip to main content

Patisiran Disease Interactions

There are 3 disease interactions with patisiran.

Moderate

Patisiran (applies to patisiran) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Patisiran has not been studied in patients with moderate or severe hepatic impairment, therefore, caution is advised if used in these patients. No dose adjustment is necessary in patients with mild hepatic impairment (bilirubin =1 × ULN and AST >1 × ULN, or bilirubin >1.0 to 1.5 × ULN).

References

  1. (2018) "Product Information. Onpattro (patisiran)." Alnylam Pharmaceuticals
Moderate

Patisiran (applies to patisiran) severe renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Patisiran has not been studied in patients with severe renal impairment or end-stage renal disease, therefore, caution is advised if used in these patients. No dose adjustment is necessary in patients with mild or moderate renal impairment (estimated glomerular filtration rate [eGFR] =30 to <90 mL/min/1.73m2).

References

  1. (2018) "Product Information. Onpattro (patisiran)." Alnylam Pharmaceuticals
Moderate

Patisiran (applies to patisiran) vitamin A deficiency

Moderate Potential Hazard, Moderate plausibility.

Treatment with patisiran leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance of vitamin A is advised for patients receiving treatment. Caution and monitoring is advised in patients with vitamin A deficiency. Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

References

  1. (2018) "Product Information. Onpattro (patisiran)." Alnylam Pharmaceuticals

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer